Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cullinan Therapeutics

Request full access

Developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model

Cambridge, United StatesFounded 2017Biotech & Life Sciences

About Cullinan Therapeutics

Cullinan Oncology is a biopharmaceutical company focused on developing innovative cancer treatments. The company operates in the oncology market, targeting patients with various types of cancer. Cullinan employs a unique portfolio model, inspired by modern portfolio theory, to manage and develop a diverse range of oncology assets. This approach allows the company to optimize returns while mitigating risks by investing in a broad array of cancer therapies diversified across indications and mechanisms of action.

Cullinan's business model combines internal idea creation with external business development activities to identify and advance promising scientific discoveries. The company maintains a lean infrastructure with nearly zero fixed costs, ensuring capital efficiency. This allows Cullinan to quickly determine the utility of its compounds, making strategic decisions to either progress or terminate programs based on their potential.

Cullinan generates revenue through the development and commercialization of its oncology assets, either independently or through partnerships with other pharmaceutical companies. By advancing therapies from preclinical stages to Phase 2 clinical trials, Cullinan aims to bring transformative cancer treatments to market, improving the standard of care for patients.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021
Employees
128
Open positions
None listed
Dealroom signal
76.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Investment activity
1 company, latest Feb 2019
Capital deployed
$0
Preferred round
Unknown

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Apr 2024 $280M — Venrock · Invus · Adage Capital · Rock Springs Capital ↗
IPOOther financing Jan 2021 $287M $870M Undisclosed —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Cullinan Therapeutics website traffic

Latest recorded traffic for Cullinan Therapeutics is 2.3K monthly website visits, up 3733.3% over the last three months. Cullinan Therapeutics's team declined 1.5% over the past year.

Latest monthly visits2.3K 3-month web change+3733.3% 1-year team growth-1.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cullinan Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Cullinan Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

25 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • F2 Ventures
  • MPM BioImpact

Series B and later20 investors entered at this stage

  • Foresite Capital
  • Cowen Group
  • Schooner Capital
  • Rock Springs Capital
  • Nextech Invest
  • Venrock
  • OrbiMed
  • BVF Partners
  • Eventide Asset Management
  • Boxer Capital
  • Logos Capital
  • The Baupost Group
  • Invus
  • Adage Capital
  • RTW Investments
  • Avidity Partners
  • Surveyor Capital
  • Blue Owl Capital
  • Braidwell
  • Paradigm BioCapital

Other known investors3 additional known investors

  • Cullinan Therapeutics
  • Helmholtz Association - Helmholtz Gemeinschaft
  • Taiho Ventures
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States99%
🇩🇪 Germany1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cullinan Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cullinan Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.